Global Central Nervous System Treatment Market

Central Nervous System Treatment Market Size, Share, Growth Analysis, By Disease Type(Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative diseases), By Drug class(Immunomodulatory drugs, interferons, Decarboxylase Inhibitors, Dopamine Agonists), By Drug Type(Biologics, Non-Biologics), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35B2179 | Region: Global | Published Date: February, 2024
Pages: 260 | Tables: 96 | Figures: 76

Central Nervous System Treatment Market Regional Insights

By holding the greatest revenue share of 49.3%, North America dominated the market for CNS therapeutics. The presence of large corporations and efforts made by major medical organizations to create novel medicines for various central nervous system ailments are the factors anticipated to enhance the total market share.

With the second leading position, Europe followed the United States. This can be attributed to the advantageous reimbursement practices and broad access to healthcare provided by the public healthcare systems like the National Health Service (NHS) of the United Kingdom. A spectacular CAGR is predicted for the Asia-Pacific countries due to a number of causes, including an ageing population, changing healthcare infrastructure, a higher engagement of countries that produce biosimilar and over-the-counter drugs, and an increase in neurological illnesses.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Central Nervous System Treatment Market size was valued at USD 120.64 billion in 2019 and is poised to grow from USD 128.29 billion in 2023 to USD 209.2 billion by 2031, growing at a CAGR of 6.3% in the forecast period (2024-2031).

Mergers, acquisitions, and partnerships are among the important market trends that are present. Major players in the market who are developing novel therapeutics for the treatment of disorders of the central nervous system have agreements with rival firms for distribution and research and development. For instance, Biogen and Sangamo Therapeutics reached an agreement to develop novel gene therapy medications for a range of neurological illnesses. The prospects of the CNS therapeutics market would be greatly improved by strategic actions implemented by leading businesses. 'Pfizer Inc.', 'Novartis International AG', 'Johnson & Johnson', 'GlaxoSmithKline plc', 'Merck & Co., Inc.', 'AbbVie Inc.', 'Sanofi S.A.', 'Eli Lilly and Company', 'AstraZeneca plc', 'Biogen Inc.', 'Teva Pharmaceutical Industries Ltd.', 'UCB S.A.', 'Boehringer Ingelheim International GmbH', 'Bristol-Myers Squibb Company', 'Ipsen S.A.', 'Lundbeck A/S', 'Otsuka Holdings Co., Ltd.', 'Sunovion Pharmaceuticals Inc.', 'Takeda Pharmaceutical Company Limited', 'Vertex Pharmaceuticals Incorporated'

The frequency and incidence of neurological illnesses, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease, among others, are rapidly rising globally. In the upcoming years, the market's growth is expected to be significantly impacted by this increase. On the other side, countries with an increasing geriatric population are also experiencing an upsurge in the prevalence of Alzheimer's disease. For instance, the Alzheimer's Association estimates that more than five million people worldwide already suffer from Alzheimer's disease, and that figure is expected to increase to 14 million by the year 2050. 

By holding the greatest revenue share of 49.3%, North America dominated the market for CNS therapeutics. The presence of large corporations and efforts made by major medical organizations to create novel medicines for various central nervous system ailments are the factors anticipated to enhance the total market share.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Central Nervous System Treatment Market

Report ID: SQMIG35B2179

$5,300
BUY NOW GET FREE SAMPLE